Case Report| Volume 44, ISSUE 3, P254-258, March 2022

A case of bilateral limbic and recurrent unilateral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibody positivity

Published:November 18, 2021DOI:



      Anti-myelin oligodendrocyte glycoprotein (MOG) antibody can be detected not only in acute disseminated encephalomyelitis or optic neuritis but also in limbic or cortical encephalitis. However, no previous reports have demonstrated a relapsing case of these two types of encephalitis.

      Case report

      An 11-year-old girl presented with fever, headache, abnormal behavior, focal impaired awareness seizures (FIAS) on the left side, and MRI hyperintensities in the bilateral amygdala, hippocampus, and right posterior temporal cortex. The symptoms were alleviated with two courses of intravenous methylprednisolone (IVMP) and one course of immunoglobulin. At 16 years of age, the patient returned with left-sided headache and MRI hyperintensities in the left temporal, parietal, and insular cortices, which improved after 3 courses of IVMP. Oral prednisolone (PSL) was tapered over 6 months, when FIAS reappeared on the right side of the body. MRI showed recurrence in the same regions as in the second episode. She received 3 courses of IVMP, followed by gradually tapered PSL without relapse for 1.5 year. Anti-MOG antibodies were positive in both serum and the cerebrospinal fluid prior to treatment in all three episodes.


      Our results revealed that anti-MOG antibody-related bilateral limbic and unilateral cortical encephalitis can manifest with a variety of phenotypes over time in the same patient.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Brain and Development
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Reindl M.
        • Di Pauli F.
        • Rostásy K.
        • Berger T.
        The spectrum of MOG autoantibody-associated demyelinating diseases.
        Nat Rev Neurol. 2013; 9: 455-461
        • Sakuma H.
        • Kohyama K.
        • Park I.K.
        • Miyakoshi A.
        • Tanuma N.
        • Matsumoto Y.
        Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats.
        Brain. 2004; 127: 2201-2213
        • Jarius S.
        • Paul F.
        • Aktas O.
        • Asgari N.
        • Dale R.C.
        • de Seze J.
        • et al.
        MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
        J Neuroinflammation. 2018; 15: 134
        • Hacohen Y.
        • Wong Y.Y.
        • Lechner C.
        • Jurynczyk M.
        • Wright S.
        • Konuskan B.
        • et al.
        Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
        JAMA Neurol. 2018; 75: 478-487
        • Bruijstens A.L.
        • Lechner C.
        • Flet-Berliac L.
        • Deiva K.
        • Neuteboom R.F.
        • Hemingway C.
        • et al.
        EU paediatric MOG consortium consensus: Part 1–Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
        Eur J Paediatr Neurol. 2020; 29: 2-13
        • Ogawa R.
        • Nakashima I.
        • Takahashi T.
        • Kaneko K.
        • Akaishi T.
        • Takai Y.
        • et al.
        MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.
        Neurol Neuroimmunol Neuroinflamm. 2017; 4: e322
        • Hamid S.H.M.
        • Whittam D.
        • Saviour M.
        • Alorainy A.
        • Mutch K.
        • Linaker S.
        • et al.
        Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease.
        JAMA Neurol. 2018; 75: 65-71
        • Uchigami H.
        • Arai N.
        • Sekiguchi M.
        • Ogawa A.
        • Yasuda T.
        • Seto A.
        • et al.
        Anti-myelin oligodendrocyte glycoprotein antibody-positive acute disseminated encephalomyelitis mimicking limbic encephalitis: A case report.
        Mult Scler Relat Disord. 2020; 38: 101500
        • Wang L.
        • ZhangBao J.
        • Zhou L.
        • Zhang Y.
        • Li H.
        • Li Y.
        • et al.
        Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China.
        Eur J Neurol. 2019; 26: 168-174
        • Takasone K.
        • Usuda M.
        • Yoshinaga T.
        • Sekijima Y.
        Limbic encephalitis with anti-myelin oligodendrocyte glycoprotein antibody.
        Intern Med. 2020; 59: 1465-1466
        • Baumann M.
        • Bartels F.
        • Finke C.
        • Adamsbaum C.
        • Hacohen Y.
        • Rostásy K.
        • et al.
        EU paediatric MOG consortium consensus: Part 2–Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
        Eur J Paediatr Neurol. 2020; 29: 14-21
        • Graus F.
        • Titulaer M.J.
        • Balu R.
        • Benseler S.
        • Bien C.G.
        • Cellucci T.
        • et al.
        A clinical approach to diagnosis of autoimmune encephalitis.
        Lancet Neurol. 2016; 15: 391-404
        • Ramanathan S.
        • Mohammad S.
        • Tantsis E.
        • Nguyen T.K.
        • Merheb V.
        • Fung V.S.C.
        • et al.
        Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
        J Neurol Neurosurg Psychiatry. 2018; 89: 127-137
      1. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017;140:3128-38.

        • Bruijstens A.L.
        • Wendel E.-M.
        • Lechner C.
        • Bartels F.
        • Finke C.
        • Breu M.
        • et al.
        EU paediatric MOG consortium consensus: Part 5–Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
        Eur J Paediatr Neurol. 2020; 29: 41-53
        • Hino-Fukuyo N.
        • Haginoya K.
        • Takahashi T.
        • Nakashima I.
        • Fujihara K.
        • Takai Y.
        • et al.
        Long-term outcome of a group of Japanese children with myelin-oligodendrocyte glycoprotein encephalomyelitis without preventive immunosuppressive therapy.
        Brain Dev. 2019; 41: 790-795